NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

The differences in the time of randomization varies with each clinical trial. Each trial has its own protocol. In some cases it’s a difference of weeks, in other cases it may be a difference of a couple of months.

I believe it would be too imprecise and arbitrary to assume the impact would be the same for all of the contemporaneous control trials. I only felt comfortable reporting the numbers as they are officially reported for each study. I included the study information for each of the 4 trials, and I think the reader can lookup each trial and make an attempt to reconcile any randomization differences if they feel inclined.

The bottom line for me is: the overall survival benefits of DCVax-L are very significant and are undeniable. The Stupp protocol was approved by the FDA (and other regulatory authorities around the world) for all Glioblastoma patients, regardless of MGMT status or gene type, and the Stupp protocol only had a mOS benefit of 2.4 months.

I think DCVax-L is a “slam dunk”...